EGRX News and Press, Eagle Pharmaceuticals Inc. From 08/30/22

WOODCLIFF LAKE, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the...

Eagle Pharmaceuticals ( NASDAQ: EGRX ) announced Thursday that a federal appeals court ruled the company's blood pressure therapy vasopressin did not infringe on any of the patents claimed by Par Pharmaceutical, Inc., a unit of the generic drug maker Endo International ( END...

WOODCLIFF LAKE, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware ...

Image source: The Motley Fool. Eagle Pharmaceuticals (NASDAQ: EGRX) Q2 2022 Earnings Call Aug 09, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Eagle Pharmaceuticals (EGRX) Q2 2022 Earnings Call Transcript

Eagle Pharmaceuticals, Inc. (EGRX) Q2 2022 Earnings Conference Call August 09, 2022 8:30 AM ET Company Participants Lisa Wilson – Investor Relations Scott Tarriff – President and Chief Executive Officer Mike Greenberg – Vice President-Medical...

Eagle Pharmaceuticals press release ( NASDAQ: EGRX ): Q2 Non-GAAP EPS of $1.56 misses by $1.80 . Revenue of $74.1M (+54.0% Y/Y) misses by $42.79M . For further details see: Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M mis...

• Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share • Total revenue for Q2 2022 was $74.1 million, compared to $48.1 million in Q2 2021, primarily reflecting product sales of ...

-- ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity -- -- Approval for post-operative respiratory depression expected in 2026 and community drug overdose thereafter -- -- ENA-001 works peripherally by...

Eagle Pharmaceuticals ( NASDAQ: EGRX ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is $3.36 (+261.3% Y/Y) and the consensus Revenue Estimate is $116.89M (+142.9% Y/Y). Over the last 2 years, EGRX ...

WOODCLIFF LAKE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 second quarter financial results on Tuesday, August 9, 2022, before the market ope...